Trials / Completed
CompletedNCT00152386
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 950 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab pegol (CDP870) |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2005-09-09
- Last updated
- 2020-12-01
Locations
76 sites across 13 countries: United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Israel, Latvia, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00152386. Inclusion in this directory is not an endorsement.